Evoendo
Centennial, US · Founded 2017 · United States corporation · 19 employees on LinkedIn · 1 known investors
EvoEndo makes an FDA-cleared endoscopy system for sedation-free transnasal and traditional transoral procedures in adult and pediatric patients. Its offering combines a single-use ultra-slim flexible gastroscope with four-way steering, a portable controller, and a virtual reality-based patient distraction system, aimed at gastroenterologists treating conditions such as eosinophilic esophagitis.
Founders & leadership
Evoendo was founded in 2017 by Joel Friedlander, Emily DeBoer, Robin Deterding, and Jeremy Prager.
JF
Joel FriedlanderinCo-founder
ED
Emily DeBoerCo-Founder
RD
Robin DeterdingCo-Founder
JP
Jeremy PragerCo-Founder
JH
Jonathan HartmannExecutive
RH
Ryan HartmaninExecutive
Board
BL
Betsy LahueBoard director
DB
David BunningBoard director
CR
Chris RowlandBoard director
JH
Jeff HarringtonBoard director
CT
Carl TraynorBoard director
DP
David PierceBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.7M disclosed across 3 rounds · 2018–2024
▶$2.3MraisedAug 2024 · 4 investors · Other Health CareRule 506(b)
▶$2.3MraisedAug 2024 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Betsy LahueDirector
- David BunningDirector
- Chris RowlandDirector
- Jeff HarringtonDirector
- Joel FriedlanderExecutive Officer, Director
- Jonathan HartmannExecutive Officer, Director
- Carl TraynorDirector
- David PierceDirector
- Ryan HartmanExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, United States
- Federal exemptions
- 06b
▶$1.9MraisedDec 2019 · 5 investors · Other Health CareRule 506(b)
▶$1.9MraisedDec 2019 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeff HarringtonDirector
- Jeremy PragerDirector
- Robin DeterdingExecutive Officer, Director
- Joel FriedlanderExecutive Officer, Director
- Emily DeBoerDirector
- Offering amount
- $2.5M
- Amount sold
- $1.9M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$500KraisedMar 2018 · 3 investors · Other Health CareRule 506(b)
▶$500KraisedMar 2018 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Emily DeBoerDirector
- Robin DeterdingExecutive Officer, Director
- Jeremy PragerDirector
- Joel FriedlanderExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- Proceeds to insiders
- $2.7K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBoston Scientific14 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Olympusamerica11 shared keywordsOlympus America develops medical technology for gastroenterology and endoscopy, including endoscopes and procedural devices used by clinicians. It also invests in medical device startups through its Olympus Innovation Ventures arm.
Rf Surgical10 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Integrated Endoscopy9 shared keywordsIntegrated Endoscopy develops single-use rigid endoscopes, including the NUVIS wireless single-use arthroscope that provides high-definition optics for arthroscopic procedures. The product is aimed at orthopedic surgeons and medical facilities to reduce the risk of cross-infection and optics damage.
Companies competing with Evoendo for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Evoendo do?
- EvoEndo makes an FDA-cleared endoscopy system for sedation-free transnasal and traditional transoral procedures in adult and pediatric patients. Its offering combines a single-use ultra-slim flexible gastroscope with four-way steering, a portable controller, and a virtual reality-based patient distraction system, aimed at gastroenterologists treating conditions such as eosinophilic esophagitis.
- Who founded Evoendo?
- Evoendo was founded by Joel Friedlander, Emily DeBoer, Robin Deterding, Jeremy Prager in 2017.
- Who are Evoendo's investors?
- Evoendo's investors include Allerfund Ventures, Llc.
- How much funding has Evoendo raised?
- Evoendo has disclosed $4.7M raised across 3 rounds.
- Where is Evoendo headquartered?
- Evoendo is headquartered in Centennial, US.